摘要
多发性骨髓瘤(MM)是一种克隆浆细胞异常增殖的恶性疾病,在很多国家是血液系统第2位常见恶性肿瘤,多发于老年,目前仍无法治愈。随着新药不断问世及检测手段的提高,MM的诊断和治疗得以不断改进和完善。本次指南修订中增加了达雷妥尤单抗联合治疗部分及相关注意事项,在难治复发性MM部分增加了嵌合抗原受体T细胞免疫疗法,强调自体造血干细胞移植对于适合移植患者仍然具有不可替代的地位。
Multiple myeloma(MM)is a clonal plasma cell disorder,the second most hematological malignancy.MM mainly develops in elderly people and remains incurable at present.With the development of novel agents and advances of laboratory evaluation,the diagnosis and treatment of MM have been significantly improved.In this version,an anti-CD38 monoclonal antibody,Daratumumab,based regimens and related concerns were appended.The chimeric antigen receptor T cell(CAR-T)immunotherapy was updated in the section of relapse and refractory myeloma.Again,autologous stem cell transplantation(ASCT)is still the standard consolidation after front-line therapy for transplant candidates with MM.
作者
无
黄晓军
无;Huang Xiaojun(Chinese Hematology Association;Chinese Society of Hematology;Chinese Myeloma Committee-Chinese Hematology Association;Department of Hematology,Peking University People's Hospital,Peking University Institute o f Hematology,National Clinical Research Center for Hematologic Disease,Beijing 100044)
出处
《中华内科杂志》
CAS
CSCD
北大核心
2020年第5期341-346,共6页
Chinese Journal of Internal Medicine
关键词
多发性骨髓瘤
指南
诊断
治疗
Multiple myeloma
Guideline
Diagnosis
Treatment
